Jiaxin Zhao

Northwestern Polytechnical University 127 West Youyi Road Xi'an 710072 China
Youyi, 710072, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

3D printable organic room-temperature phosphorescent materials and printed real-time sensing and display devices.

3D printable organic room-temperature phosphorescent materials and printed real-time sensing and display devices.

Journal: Chemical science

Published: January 14, 2025

Incidence and Risk of Fatal Adverse Events in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor 2-Targeted Agents: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials.

Incidence and Risk of Fatal Adverse Events in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor 2-Targeted Agents: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials.

Journal: Frontiers in medicine

Published: May 22, 2019

Corrigendum to "Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy" [Crit. Rev. Oncol./Hematol. 128 (August) (2018) 110-117].

Corrigendum to "Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy" [Crit. Rev. Oncol./Hematol. 128 (August) (2018) 110-117].

Journal: Critical reviews in oncology/hematology

Published: March 02, 2019

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients.

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients.

Journal: Journal for immunotherapy of cancer

Published: December 19, 2018

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events.

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events.

Journal: Journal for immunotherapy of cancer

Published: August 08, 2018

Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma.

Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma.

Journal: International journal of cancer

Published: April 23, 2018

Impact of hormone receptor status on the efficacy of HER2-targeted treatment.

Impact of hormone receptor status on the efficacy of HER2-targeted treatment.

Journal: Endocrine-related cancer

Published: April 09, 2018

Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy.

Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy.

Journal: Critical reviews in oncology/hematology

Published: February 07, 2018

High Expression of Vimentin is Associated With Progression and a Poor Outcome in Glioblastoma.

High Expression of Vimentin is Associated With Progression and a Poor Outcome in Glioblastoma.

Journal: Applied immunohistochemistry & molecular morphology : AIMM

Published: August 25, 2016

SRPX2 Enhances the Epithelial-Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Cells.

SRPX2 Enhances the Epithelial-Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Cells.

Journal: Cellular and molecular neurobiology

Published: July 22, 2015

SEMA6A is a prognostic biomarker in glioblastoma.

SEMA6A is a prognostic biomarker in glioblastoma.

Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Published: April 12, 2015

CXCR4 over-expression and survival in cancer: a system review and meta-analysis.

CXCR4 over-expression and survival in cancer: a system review and meta-analysis.

Journal: Oncotarget

Published: November 23, 2014

Showing 1-12 of 14

Last Updated: 09/26/2026